Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis

被引:17
作者
Wang, Wei [1 ]
Pan, Fan [2 ]
Lin, Xinrong [2 ]
Yuan, Jiakai [2 ]
Tao, Chunyu [2 ]
Wang, Rui [1 ,2 ]
机构
[1] Nanjing Med Univ, Jinling Hosp, Dept Med Oncol, Nanjing, Peoples R China
[2] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing, Peoples R China
关键词
ferroptosis; hepatocellular carcinoma; prognostic model; immune; drug resistance; bioinformatics analysis; DYSREGULATED PATHWAYS; MECHANISMS; EXPRESSION; PREDICTS; GROWTH; CELLS; MODEL;
D O I
10.3389/fgene.2022.907331
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer with a high fatality rate and dismal prognosis because of frequent recurrence and lack of efficient therapies. Ferroptosis is a recently recognized iron-dependent cell death distinct from necroptosis and apoptosis. The relationship between ferroptosis-related hub gene expression and prognosis in HCC remains to be further elucidated.Methods: Ferroptosis-related genes from the FerrDb database and the mRNA sequencing data and clinical information of HCC patients were obtained from The Cancer Genome Atlas (TCGA) database. The least absolute shrinkage and selection operator (LASSO) Cox regression was applied to identify a prognostic signature consisting of five ferroptosis-related hub genes in the TCGA cohort. The International Cancer Genome Consortium (ICGC) database was utilized to validate the reliability of the signature. Functional enrichment and immune-related analysis, including single-sample gene set enrichment analysis (ssGSEA), immune checkpoints, TIP-related genes, tumor stemness, and m6A-related genes, were performed to analyze the underlying mechanism. Additionally, the correlations between ferroptosis and drug resistance were evaluated using the NCI-60 database.Results: A 5-hub-gene signature associated with ferroptosis was constructed by multivariate Cox regression analysis to stratify patients into two risk groups. Patients with high risk had worse prognosis than those with low risk. Multivariate Cox regression analysis uncovered that the risk score was an independent prognostic indicator. We also proved the signature's predictive capacity using the Kaplan-Meier method and receiver operating characteristic (ROC) curve analysis. Functional analysis showed that nuclear division and the cell cycle were enriched. Immune-related analysis revealed that the signature was enriched in immune-related pathways. Moreover, the risk signature was significantly associated with immune cell infiltration, immune checkpoints, TIP-related genes, tumor stem cells, as well as m6A-related genes. Furthermore, these genes were crucial regulators of drug resistance.Conclusion: We identified and validated a novel hub gene signature that is closely associated with ferroptosis as a new and efficient biomarker with favorable potential for predicting the prognosis of HCC patients. In addition, it also offers new insights into the molecular mechanisms of HCC and provides an effective approach for the treatment of HCC. Further studies are necessary to validate the results of our study.
引用
收藏
页数:19
相关论文
共 70 条
[1]   Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J].
Allemani, Claudia ;
Matsuda, Tomohiro ;
Di Carlo, Veronica ;
Harewood, Rhea ;
Matz, Melissa ;
Niksic, Maja ;
Bonaventure, Audrey ;
Valkov, Mikhail ;
Johnson, Christopher J. ;
Esteve, Jacques ;
Ogunbiyi, Olufemi J. ;
Azevedo e Silva, Gulnar ;
Chen, Wan-Qing ;
Eser, Sultan ;
Engholm, Gerda ;
Stiller, Charles A. ;
Monnereau, Alain ;
Woods, Ryan R. ;
Visser, Otto ;
Lim, Gek Hsiang ;
Aitken, Joanne ;
Weir, Hannah K. ;
Coleman, Michel P. .
LANCET, 2018, 391 (10125) :1023-1075
[2]   Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].
Ally, Adrian ;
Balasundaram, Miruna ;
Carlsen, Rebecca ;
Chuah, Eric ;
Clarke, Amanda ;
Dhalla, Noreen ;
Holt, Robert A. ;
Jones, Steven J. M. ;
Lee, Darlene ;
Ma, Yussanne ;
Marra, Marco A. ;
Mayo, Michael ;
Moore, Richard A. ;
Mungall, Andrew J. ;
Schein, Jacqueline E. ;
Sipahimalani, Payal ;
Tam, Angela ;
Thiessen, Nina ;
Cheung, Dorothy ;
Wong, Tina ;
Brooks, Denise ;
Robertson, A. Gordon ;
Bowlby, Reanne ;
Mungall, Karen ;
Sadeghi, Sara ;
Xi, Liu ;
Covington, Kyle ;
Shinbrot, Eve ;
Wheeler, David A. ;
Gibbs, Richard A. ;
Donehower, Lawrence A. ;
Wang, Linghua ;
Bowen, Jay ;
Gastier-Foster, Julie M. ;
Gerken, Mark ;
Helsel, Carmen ;
Leraas, Kristen M. ;
Lichtenberg, Tara M. ;
Ramirez, Nilsa C. ;
Wise, Lisa ;
Zmuda, Erik ;
Gabriel, Stacey B. ;
Meyerson, Matthew ;
Cibulskis, Carrie ;
Murray, Bradley A. ;
Shih, Juliann ;
Beroukhim, Rameen ;
Cherniack, Andrew D. ;
Schumacher, Steven E. ;
Saksena, Gordon .
CELL, 2017, 169 (07) :1327-+
[3]   Challenges in liver cancer and possible treatment approaches [J].
Anwanwan, David ;
Singh, Santosh Kumar ;
Singh, Shriti ;
Saikam, Varma ;
Singh, Rajesh .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (01)
[4]   MAPK3 deficiency drives autoimmunity via DC arming [J].
Bendix, Ivo ;
Pfueller, Caspar F. ;
Leuenberger, Tina ;
Glezeva, Nadezhda ;
Siffrin, Volker ;
Mueller, Yasmin ;
Prozorovski, Timour ;
Hansen, Wiebke ;
Topphoff, Ulf Schulze ;
Loddenkemper, Christoph ;
Zipp, Frauke ;
Waiczies, Sonia .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (05) :1486-1495
[5]   Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy [J].
Chen, Hai-Long ;
OuYang, Han-Yue ;
Le, Yong ;
Jiang, Peng ;
Tang, Hui ;
Yu, Zi-Shan ;
He, Min-Ke ;
Tang, Yun-Qiang ;
Shi, Ming .
CANCER MEDICINE, 2018, 7 (11) :5339-5350
[6]   Clinicopathological and prognostic significance of GLUT1 in breast cancer A meta-analysis [J].
Deng, Yu ;
Zou, Jialing ;
Deng, Ting ;
Liu, Junying .
MEDICINE, 2018, 97 (48)
[7]   Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma [J].
Dietrich, Peter ;
Gaza, Anne ;
Wormser, Laura ;
Fritz, Valerie ;
Hellerbrand, Claus ;
Bosserhoff, Anja Katrin .
NEOPLASIA, 2019, 21 (03) :257-268
[8]   Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option [J].
Dietrich, Peter ;
Freese, Kim ;
Mahli, Abdo ;
Thasler, Wolfgang Erwin ;
Hellerbrand, Claus ;
Bosserhoff, Anja Katrin .
ONCOTARGET, 2018, 9 (03) :3605-3618
[9]   Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death [J].
Dixon, Scott J. ;
Lemberg, Kathryn M. ;
Lamprecht, Michael R. ;
Skouta, Rachid ;
Zaitsev, Eleina M. ;
Gleason, Caroline E. ;
Patel, Darpan N. ;
Bauer, Andras J. ;
Cantley, Alexandra M. ;
Yang, Wan Seok ;
Morrison, Barclay, III ;
Stockwell, Brent R. .
CELL, 2012, 149 (05) :1060-1072
[10]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502